You are here

Roche

Roivant’s $7B Roche deal was a ‘moment of opportunity,’ CEO says

BioPharma Dive

Tue, 10/31/23 - 09:32 pm

Roche, Lilly or Pfizer: Who's the Winner in IBD Wars?

Motley Fool

Sun, 10/29/23 - 08:44 pm

ulcerative colitis

Crohn's Disease

FDA Approves Genentech’s Vabysmo for the Treatment of Retinal Vein Occlusion (RVO)

BioSpace

Fri, 10/27/23 - 11:34 am

retinal vein occlusion

Roche settles US patent lawsuit against Biogen over blockbuster arthritis drug

Reuters

Mon, 10/23/23 - 05:11 pm

Roche pays $7.1B to Roivant for rights to Telavant’s IBD candidate

BioSpace

Mon, 10/23/23 - 10:35 am

ulcerative colitis

Crohn’s disease

Lung Cancer Takes Center Stage at ESMO Congress 2023 With New Drugs, More Options

OBR Oncology

Fri, 10/20/23 - 10:05 am

non-small cell lung cancer

Roche drops oral eye disease drug after completing phase 2, pulls back from solid tumor bispecific

Fierce Biotech

Thu, 10/19/23 - 11:36 am

diabetic retinopathy

bispecific antibodies

Roche's Q3 sales down 3% on currency headwinds, drop in COVID sales

Reuters

Thu, 10/19/23 - 10:03 am

Roche pays $50M upfront to Monte Rosa in molecular glue deal

Fierce Biotech

Tue, 10/17/23 - 09:46 pm

protein degradation

Roche builds gene therapy portfolio with SpliceBio deal

Pharmaphorum

Tue, 10/17/23 - 11:00 am

Spark Therapeutics

inherited retinal disease

Amid Eylea showdown, Roche's Vabysmo shows durability in retinal vein occlusion

Fierce Pharma

Wed, 10/11/23 - 10:13 am

retinal vein occlusion

Roche preps for filings after subcutaneous Ocrevus matches up to IV formulation in phase 3 study

Fierce Pharma

Wed, 10/11/23 - 10:07 am

multiple sclerosis

clinical trials

Majority of Newborn Babies With Spinal Muscular Atrophy (SMA) Treated With Genentech’s Evrysdi Able to Sit Independently After 1 Year of Treatment

BioSpace

Wed, 10/4/23 - 09:41 am

clinical trials

Biogen nabs FDA nod for biosimilar version of Roche's blockbuster Actemra

Fierce Pharma

Mon, 10/2/23 - 11:48 am

autoimmune disease

In label expansion bid, AbbVie and Roche's Venclexta falls short in multiple myeloma subset

Fierce Pharma

Fri, 09/29/23 - 12:13 pm

Multiple Myeloma

Roche pays Ionis $60M upfront to license RNA-targeting Alzheimer's, Huntington's programs

Fierce Biotech

Wed, 09/27/23 - 10:14 am

Ionis Pharmaceuticals

Alzheimer's disease

Huntington's disease

Roche condemns 'act of counterfeiting' as authorities in Pakistan crack down on unapproved Avastin use

Fierce Pharma

Mon, 09/25/23 - 07:42 pm

drug counterfeiting

Roche scores—again—in hemophilia drug patent case against Takeda

Fierce Pharma

Thu, 09/21/23 - 11:47 am

Roche hits FDA delay with subcutaneous version of Tecentriq amid manufacturing process changes

Fierce Pharma

Thu, 09/7/23 - 10:53 pm

Roche Sees Return on $310M Investment with Alnylam’s Phase II Hypertension Win

BioSpace

Thu, 09/7/23 - 10:49 pm

clinical trials

Pages